Technology Platform

The RuCIA Platform

Rudacure Ion Channel Innovative Assessment — the core engine integrating AI-driven molecular prediction with high-throughput electrophysiological validation.

Ion Channel Mastery

Specialized in ion channels governing pain and sensory signals including TRPV1, TRPA1, and TRPV4. AI predicts channel-ligand interactions to discover selective drug candidates.

AI Molecular Simulation

Molecular-level simulation eliminates off-target effects preemptively. Fully resolved the hyperthermia side effect of first-generation TRPV1 antagonists.

Electrophysiology Validation

High-throughput electrophysiology validation using patch clamp technology. Confirms AI predictions against actual ion channel activity data.

CRO Services

Specialized electrophysiology CRO services. Customized efficacy evaluation with animal models for ocular and sensory diseases.

Molecular Dynamics

Molecular Dynamics in Action

RuCIA simulates membrane proteins at atomic resolution within a realistic lipid environment, revealing the stability and conformational dynamics of target–ligand binding. This is where AI predictions are validated by physics-based dynamics.

The TRPV4 ion channel–RhoA complex simulated within a real all-atom lipid bilayer (POPC membrane): green is the lipid membrane, the blue/purple surface is the transmembrane channel (TRPV4 tetramer), magenta the intracellular binding partner (RhoA). RuCIA studies membrane proteins in a real membrane environment — together with their intracellular partners, not in water alone.

TRP channel–ligand binding dynamics in a lipid membrane

Conformational changes in a membrane environment

Target–ligand interaction simulation

Competitive Advantage

RuCIA vs Traditional Drug Discovery

Metric	Traditional	RuCIA	Gap
Development Time	10-15 years	3-5 years	70%
Candidate Selectivity	Trial & Error	100% AI-Predicted	—
Side Effects (Hyperthermia)	Unresolved	Fully Resolved	—
Cost Efficiency	$2.6B Average	Significantly Reduced	—

Beyond the Signal

Ion channels are key regulators of pain, temperature sensation, and ocular surface homeostasis. RuCIA precisely modulates the source of these signals, treating causes rather than symptoms.

In the post-opioid era, where FDA/EMA prioritize non-addictive alternatives, RudaCure's TRPV1 platform is a strategic partnership target for global pharmaceutical companies.